For your warrior patients with sickle cell disease
The Power of VOC Prevention
ADAKVEO® (crizanlizumab) was developed for SCD and is the first and only once-monthly treatment for the prevention of vaso-occlusive crises1
Consequences of VOCs
VOCs are the clinical hallmark of SCD.2 Learn why preventing VOCs is important for your patients.
VOC Prevention
ADAKVEO was proven to prevent VOCs across all patient types in the SUSTAIN clinical trial.1
The History of ADAKVEO
Learn about the scientific discoveries that led to the development of ADAKVEO.
ADAKVEO Mechanism of Action
ADAKVEO is the first and only approved targeted monoclonal antibody that works by inhibiting P-selectin-mediated multicellular adhesion in SCD—thereby preventing vaso-occlusion.1,3
See how the pathogenesis of VOCs involves more than sickled red blood cells
INDICATION
ADAKVEO® (crizanlizumab) IV infusion is indicated for the prevention of vaso-occlusive crises (VOCs) in sickle cell disease patients aged 16 years and over.
SCD, sickle cell disease; VOCs, vaso-occlusive crises.
References:
1. Adakveo [summary of product characteristics]. Basel, Switzerland: Novartis Pharma AG; 2021.
2. Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: a critical reappraisal. Blood. 2012;120(18):3647-3656.
3. National Heart, Lung, and Blood Institute. SBIR Success Stories. NHLBI funding leads to promising drug candidate to prevent sickle cell pain. http://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/small-business-program/sbir-success-stories/nhlbi-funding-leads-promising-drug-candidate-prevent-sickle-cell-pain. Accessed November 8, 2021.